<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Efficacy of <z:chebi fb="2" ids="46081">fluconazole</z:chebi> (FLCZ), an anti-fungal agent of <z:chebi fb="0" ids="38597">triazole</z:chebi> derivatives, was evaluated in patients with systemic <z:chebi fb="0" ids="16551">mycoses</z:chebi> and suspected <z:chebi fb="0" ids="16551">mycoses</z:chebi> associated with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> including <z:hpo ids='HP_0001909'>leukemia</z:hpo>, <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Plasma beta-D-glycan levels, the differences between the levels determined toxicolor test and in endospecy test, were also investigated </plain></SENT>
<SENT sid="2" pm="."><plain>Fourteen patients with systemic <z:chebi fb="0" ids="16551">mycoses</z:chebi> and 31 patients with suspected mycotic <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> were treated with intravenous administration of FLCZ at a daily dose of 400 mg </plain></SENT>
<SENT sid="3" pm="."><plain>Excellent to good responses were observed in 4 of the 14 patients (28.6%) with definitive diagnosis of <z:e sem="disease" ids="C0026946" disease_type="Disease or Syndrome" abbrv="">mycosis</z:e>, and in 18 of the 31 patients (58.1%) with suspected <z:e sem="disease" ids="C0026946" disease_type="Disease or Syndrome" abbrv="">fungal infections</z:e>, with an overall efficacy rate of 48.9% (22/45) </plain></SENT>
<SENT sid="4" pm="."><plain>Levels of plasma beta-D-glycan correlated well with efficacies of FLCZ in 19 of 30 patients </plain></SENT>
<SENT sid="5" pm="."><plain>In several cases, however, plasma <z:chebi fb="0" ids="28793">beta-D-glucan</z:chebi> levels were low during the entire course of treatment </plain></SENT>
<SENT sid="6" pm="."><plain>Even in 10 cases of definite <z:e sem="disease" ids="C0026946" disease_type="Disease or Syndrome" abbrv="">mycosis</z:e>, 4 cases showed low levels of plasma <z:chebi fb="0" ids="28793">beta-D-glucan</z:chebi> (below 15 pg/ml by repeated determinations) </plain></SENT>
<SENT sid="7" pm="."><plain>The results indicate that FLCZ is an effective agent for the treatment of severe <z:e sem="disease" ids="C0553576" disease_type="Disease or Syndrome" abbrv="">systemic fungal infections</z:e> in patients with <z:e sem="disease" ids="C1521860" disease_type="Disease or Syndrome" abbrv="">hematologic disorders</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Deep seated <z:e sem="disease" ids="C0026946" disease_type="Disease or Syndrome" abbrv="">mycosis</z:e> cannot be ruled out even when its plasma levels of <z:chebi fb="0" ids="28793">beta-D-glucan</z:chebi> are low </plain></SENT>
</text></document>